Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis.
Rosenbloom
Joel
J
Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA 19107-5541, USA.
Jiménez
Sergio A
SA
D005109:Extracellular Matrix / Q000502:physiology; D005355:Fibrosis / Q000628:therapy; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000503:physiopathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000503:physiopathology; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000502:physiology*
D047428:Protein Kinase Inhibitors; D016212:Transforming Growth Factor beta; D011505:Protein-Tyrosine Kinases